"I don't think I've ever seen this much buzz and excitement over a new approach in psychiatry in my career," says Jeffrey Conn, a pharmacologist at Vanderbilt University.
"Drug discovery is coming back to psychiatry," says Arthur Christopoulos, highlighting a renewed focus on innovative drug mechanisms showcasing potential for treating mental health conditions.
"It is still early days," states Christopoulos, cautioning that the failure of Abbvie's muscarinic drug indicates the tough landscape for emerging schizophrenia treatments.
KarXT targets muscarinic receptors, offering a new mechanism of action, contrasting with traditional schizophrenia drugs that primarily influence dopamine levels.
Collection
[
|
...
]